<DOC>
	<DOCNO>NCT00002887</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug way kill tumor cell . PURPOSE : Phase I trial study effect hydroxyurea plus combination chemotherapy patient non-small cell lung cancer .</brief_summary>
	<brief_title>Hydroxyurea Plus Combination Chemotherapy Patients With Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Estimate maximum tolerate dose hydroxyurea give combination chemotherapy regimens patient incurable non-small cell lung cancer . II . Determine toxicity combination chemotherapy regimen patient . III . Observe efficacy hydroxyurea patient incurable non-small cell lung cancer refractory front-line chemotherapy . OUTLINE : This study seek estimate maximum tolerate dose ( MTD ) hydroxyurea combination chemotherapy . Groups 3 patient take escalated dos oral hydroxyurea three time weekly daily throughout treatment cisplatin plus ( per previous regimen ) vinblastine , vindesine , vinorelbine , etoposide . Treatment continue respond stable patient 3 month beyond documentation complete remission ( minimum 4 course ) , maximum 6 course beyond documentation partial remission , 3 course beyond documentation stable disease . Patients follow every 3 week 3 month , every 6 week 3 month , every 3 month disease progression . PROJECTED ACCRUAL : An anticipated 15-30 patient enter .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vindesine</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histopathologically prove nonsmall cell lung cancer incurable surgery radiotherapy Brain metastases allow Demonstrated resistance prior chemotherapy require 1 following : Tumor growth recurrence treatment Failure tumor shrink 3 consecutive course treatment Measurable evaluable disease PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 02 Life expectancy : Greater 12 week Hematopoietic : ANC least 1,500 Platelets least 100,000 Hemoglobin least 10 g/dL Hepatic : Bilirubin le 1.5 mg/dL ( 26 micromoles/L ) AST/ALT le 1.5 time normal Renal : Creatinine le 1.6 mg/dL ( 150 micromoles/L ) Cardiovascular : No uncontrolled hypertension cardiac disease No myocardial infarction within 6 month Other : No uncontrolled diabetes No active abuse ethanol No allergy study medication No active infection serious medical condition precludes protocol treatment No dementia significantly alter mental status precludes inform consent No prior melanoma malignancy follow site : Breast Kidney Thyroid Salivary glands Endometrium No second malignancy within 5 year except : Nonmelanomatous skin cancer Carcinoma situ cervix No pregnant nursing woman Effective contraception require fertile woman PRIOR CONCURRENT THERAPY : Recovery treatmentlimiting toxicity require Biologic therapy : Not specify Chemotherapy : At least 3 week since myelosuppressive chemotherapy ( 6 week since nitrosoureas , mitomycin , highdose carboplatin ) Endocrine therapy : Not specify Radiotherapy : At least 3 week since radiotherapy unless limb limited treatment area Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2001</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
</DOC>